Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Runimotamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BTRC-4017A (RG-6194) is under development for the treatment of HER2-expressing solid tumors including adenocarcinoma of the gastroesophageal junction, gastric cancer and metastatic breast cancer. The drug candidate is a bi-specific antibody which is administered through the intravenous route. It is a new molecular entity (NME) which acts by targeting Her2 and CD3.
Genentech USA overview
Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.
For a complete picture of Runimotamab’s drug-specific PTSR and LoA scores, buy the report here.